Titlebook: Organ Directed Toxicities of Anticancer Drugs; Proceedings of the F Miles P. Hacker,John S. Lazo,Thomas R. Tritton Conference proceedings 1

Detrusor-Muscle

书目名称Organ Directed Toxicities of Anticancer Drugs影响因子(影响力)




书目名称Organ Directed Toxicities of Anticancer Drugs影响因子(影响力)学科排名




书目名称Organ Directed Toxicities of Anticancer Drugs网络公开度




书目名称Organ Directed Toxicities of Anticancer Drugs网络公开度学科排名




书目名称Organ Directed Toxicities of Anticancer Drugs被引频次




书目名称Organ Directed Toxicities of Anticancer Drugs被引频次学科排名




书目名称Organ Directed Toxicities of Anticancer Drugs年度引用




书目名称Organ Directed Toxicities of Anticancer Drugs年度引用学科排名




书目名称Organ Directed Toxicities of Anticancer Drugs读者反馈




书目名称Organ Directed Toxicities of Anticancer Drugs读者反馈学科排名

duplicate

ALLAY

Role of Iron in Anthracycline Actiononly relatively recently that attention has focused on the role of iron chemistry in this process. Interest in this problem is bound to increase as a result of recent clinical and preclinical studies which demonstrate that ICRF-187, an EDTA derivative, effectively prevents doxorubicin-induced cardia

Forage饲料

Role of Reactive Oxygen Production in Doxorubicin Cardiac Toxicity lymphomas, and carcinomas of the breast, lung, and thyroid (1). The clinical usefulness of these drugs may, however, be compromised by the development of a dose related, congestive cardiomyopathy that is sometimes fatal (2). Over the past decade, a substantial body of experimental data has been pub

懒鬼才会衰弱

Adriamycin Cardiac Toxicity — An Assessment of Approaches to Cardiac Monitoring and Cardioprotectionrolonged use could lead to progressive, refractory, irreversible and almost uniformly fatal congestive heart failure has been a major impediment to its more widespread use in the curative treatment of early cancer and to prolonging its use in responding patients with advanced disease.

传授知识

羊齿

A Trial of ICRF-187 to Selectively Protect Against Chronic Adriamycin Cardiac Toxicity: Rationale ane drugs, particularly doxorubicin (Adriamycin.), constitute some of the most active compounds available to the clinical oncologist. They have activity in both hematologic malignancies and solid tumors. Numerous efforts to improve upon their activity through analogue development or a better dose sche

narcissism

PATRI

Infirm

Bleomycin Induced Lung Injuryoxicity varies widely, from 2 to 40% (1). Risk factors in developing toxicity include age, cumulative dose, use with other cytotoxic drugs, radiation therapy and oxygen (1). The most frequent manifestation of bleomycin induced pulmonary injury is the development of a diffuse alveolar damage frequent